{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:45:10Z","timestamp":1790142310142,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":4544,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1093\/annonc\/mdm114","type":"journal-article","created":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:24:43Z","timestamp":1177979083000},"page":"1216-1223","source":"Crossref","is-referenced-by-count":102,"title":["A phase I\/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma"],"prefix":"10.1016","volume":"18","author":[{"given":"J.P.","family":"Leonard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.I.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Czuczman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Stiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Forero-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Chieffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"McKinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Finucane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm114_bb0010","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm114_bb0015","series-title":"Zevalin\u00ae (ibritumomab tiuxetan) Package Insert","first-page":"1","year":"2005"},{"key":"10.1093\/annonc\/mdm114_bb0020","first-page":"1","author":"BEXXAR\u00ae Tositumomab and Iodine I 131 Tositumomab Package Insert","year":"2005"},{"key":"10.1093\/annonc\/mdm114_bb0025","first-page":"627","article-title":"Hematopoietic stem cell transplantation for non-Hodgkin's lymphoma","volume":"17","author":"Holmberg","year":"2003","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdm114_bb0030","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/blood.V86.8.3257.3257","article-title":"Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma","volume":"86","author":"Bastion","year":"1995","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm114_bb0035","author":"Rituxan\u00ae (rituximab) Package Insert","year":"2005"},{"key":"10.1093\/annonc\/mdm114_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/sonc.2002.30154","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial","volume":"29","author":"Hainsworth","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdm114_bb0045","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm114_bb0050","first-page":"1455","article-title":"\u201cPrimatization\u201d of recombinant antibodies for immunotherapy of human diseases: a macaque\/human chimeric antibody against human CD4","volume":"10","author":"Newman","year":"1992","journal-title":"Biotechnology"},{"key":"10.1093\/annonc\/mdm114_bb0055","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1365-2567.1998.00550.x","article-title":"Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma","volume":"94","author":"Vyth-Dreese","year":"1998","journal-title":"Immunology"},{"key":"10.1093\/annonc\/mdm114_bb0060","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1182\/blood.V90.11.4297","article-title":"In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation","volume":"90","author":"Dorfman","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm114_bb0065","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood.V83.3.793.793","article-title":"In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease","volume":"83","author":"Munro","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm114_bb0070","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1182\/blood.V91.12.4708","article-title":"Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone","volume":"91","author":"Dogan","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm114_bb0075","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLM.2003.n.008","article-title":"Initial trials of Anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma","volume":"3","author":"Younes","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mdm114_bb0080","doi-asserted-by":"crossref","first-page":"7766","DOI":"10.1074\/jbc.M105902200","article-title":"Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma","volume":"277","author":"Suvas","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdm114_bb0085","first-page":"608a","article-title":"Therapeutic activity of IDEC-114 (anti-CD80) and rituximab (Rituxan\u00ae) in B-cell lymphoma","volume":"98","author":"Hariharan","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm114_bb0090","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2005.09.018","article-title":"Phase I\/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm114_bb0095","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm114_bb0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"10.1093\/annonc\/mdm114_bb0105","first-page":"3904","article-title":"Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma","volume":"6","author":"Stopeck","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm114_bb0110","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/blood.V82.9.2845.2845","article-title":"The B7\/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines","volume":"82","author":"Delabie","year":"1993","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm114_bb0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1440-1827.1998.tb03821.x","article-title":"Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease","volume":"48","author":"Nozawa","year":"1998","journal-title":"Pathol Int"},{"key":"10.1093\/annonc\/mdm114_bb0120","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/cncr.11827","article-title":"Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma","volume":"98","author":"Lyman","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm114_bb0125","author":"Campath\u00ae (Alemtuzumab) Package Insert","year":"2005"},{"key":"10.1093\/annonc\/mdm114_bb0130","author":"Herceptin\u00ae (Trastuzumab) Package Insert","year":"2005"},{"key":"10.1093\/annonc\/mdm114_bb0135","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/annonc\/mdh176","article-title":"Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma","volume":"15","author":"Tobinai","year":"2004","journal-title":"Ann Onc"},{"key":"10.1093\/annonc\/mdm114_bb0140","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0091270005277075","article-title":"Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial","volume":"45","author":"Ng","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1093\/annonc\/mdm114_bb0145","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","article-title":"Pharmacokinetic behavior of rituximab\u2014a study of different schedules of administration for heterogeneous clinical settings","volume":"27","author":"Regazzi","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1093\/annonc\/mdm114_bb0150","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm114_bb0155","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm114_bb0160","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419412143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419412143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/7\/1216\/642824\/mdm114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T13:20:09Z","timestamp":1582204809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419412143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0923753419412143"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm114","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}